Skip to main content
. 2020 Feb;26(2):298–306. doi: 10.3201/eid2602.190721

Table 2. Seropositivity and seroconversion in plasma from hand, foot and mouth disease patients infected with EV-A71, CVA6, CVA10, and CVA16 viruses, Vietnam*.

Virus Immunity status Virus, no. (%) samples
CVA6 CVA10 CVA16 EV-A71
CVA6 Seropositivity
At enrollment 2 (7) 10 (33) 5 (17) 2 (7)
At follow-up 30 (100) 9 (30) 9 (30) 3 (10)
p value <0.001 1.0 0.36 1.0

Seroconversion
28 (93)
1 (3)
7 (23)
2 (7)
CVA10 Seropositivity
At enrollment 4 (13) 9 (30) 3 (10) 3 (10)
At follow-up 6 (20) 29 (97) 4 (13) 5 (17)
p value 0.73 <0.001 1.0 0.71

Seroconversion
4 (13)
25 (83)
3 (10)
2 (7)
CVA16 Seropositivity
At enrollment 7 (23) 10 (33) 8 (27) 5 (17)
At follow-up 9 (30) 11 (37) 30 (100) 7 (23)
p value 0.77 1.0 <0.001 0.75

Seroconversion
3 (10)
2 (7)
23 (77)
2 (7)
EV-A71 Seropositivity
At enrollment 5 (17) 17 (57) 6 (20) 18 (60)
At follow-up 7 (23) 14 (47) 8 (27) 30 (100)
p value 0.75 0.61 0.76 <0.001
Seroconversion 4 (13) 1 (3) 3 (10) 17 (57)

*n = 30 for each virus. p values reflect the results of statistical analysis comparing the seropositive rates between the 2 time points (enrollment and follow-up) of the corresponding enterovirus serotypes. CV, coxsackievirus; EV, enterovirus.